|
1
|
Zhang Z, Ni C, Chen W, Wu P, Wang Z, Yin
J, Huang J and Qiu F: Expression of CXCR4 and breast cancer
prognosis: A systematic review and meta-analysis. BMC Cancer.
14:492014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Richards CE, Vellanki SH, Smith YE and
Hopkins AM: Diterpenoid natural compound C4 (Crassin) exerts
cytostatic effects on triple-negative breast cancer cells via a
pathway involving reactive oxygen species. Cell Oncol. 41:35–46.
2018. View Article : Google Scholar
|
|
3
|
Chacón RD and Costanzo MV: Triple-negative
breast cancer. Breast Cancer Res. 12 Suppl 2:S32010. View Article : Google Scholar
|
|
4
|
Foulkes WD, Smith IE and Reis-Filho JS:
Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ma H, Xu X, Clague J, Lu Y, Togawa K, Wang
SS, Clarke CA, Lee E, Park HL, Sullivan-Halley J, et al:
Recreational physical activity and risk of triple negative breast
cancer in the California Teachers Study. Breast Cancer Res.
18:622016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Wang K, Feng H, Ren W, Sun X, Luo J, Tang
M, Zhou L, Weng Y, He TC and Zhang Y: BMP9 inhibits the
proliferation and invasiveness of breast cancer cells MDA-MB-231. J
Cancer Res Clin Oncol. 137:1687–1696. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wang RN, Green J, Wang Z, Deng Y, Qiao M,
Peabody M, Zhang Q, Ye J, Yan Z, Denduluri S, et al: Bone
morphogenetic protein (BMP) signaling in development and human
diseases. Genes Dis. 1:87–105. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ye L, Bokobza SM and Jiang WG: Bone
morphogenetic proteins in development and progression of breast
cancer and therapeutic potential (Review). Int J Mol Med.
24:591–597. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Wan S, Liu Y, Weng Y, Wang W, Ren W, Fei
C, Chen Y, Zhang Z, Wang T, Wang J, et al: BMP9 regulates
cross-talk between breast cancer cells and bone marrow-derived
mesenchymal stem cells. Cell Oncol. 37:363–375. 2014. View Article : Google Scholar
|
|
10
|
García-Álvaro M, Addante A, Roncero C,
Fernández M, Fabregat I, Sánchez A and Herrera B: BMP9-induced
survival effect in liver tumor cells requires p38MAPK activation.
Int J Mol Sci. 16:20431–20448. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Lv Z, Wang C, Yuan T, Liu Y, Song T, Liu
Y, Chen C, Yang M, Tang Z, Shi Q, et al: Bone morphogenetic protein
9 regulates tumor growth of osteosarcoma cells through the
Wnt/β-catenin pathway. Oncol Rep. 31:989–994. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ren W, Sun X, Wang K, Feng H, Liu Y, Fei
C, Wan S, Wang W, Luo J, Shi Q, et al: BMP9 inhibits the bone
metastasis of breast cancer cells by downregulating CCN2
(connective tissue growth factor, CTGF) expression. Mol Biol Rep.
41:1373–1383. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ren W, Liu Y, Wan S, Fei C, Wang W, Chen
Y, Zhang Z, Wang T, Wang J, Zhou L, et al: BMP9 inhibits
proliferation and metastasis of HER2-positive SK-BR-3 breast cancer
cells through ERK1/2 and PI3K/AKT pathways. PLoS One. 9:e968162014.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zardavas D, Fumagalli D and Loi S:
Phosphatidylinositol 3-kinase/AKT/mammalian target of rapamycin
pathway inhibition: A breakthrough in the management of luminal
(ER+/HER2-) breast cancers? Curr Opin Oncol. 24:623–634. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ciruelos Gil EM: Targeting the
PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
Cancer Treat Rev. 40:862–871. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Grunt TW and Mariani GL: Novel approaches
for molecular targeted therapy of breast cancer: Interfering with
PI3K/AKT/mTOR signaling. Curr Cancer Drug Targets. 13:188–204.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL,
Kim JS and Yoo YA: Metastatic function of BMP-2 in gastric cancer
cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9
expression. Exp Cell Res. 317:1746–1762. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Shimizu T, Kayamori T, Murayama C and
Miyamoto A: Bone morphogenetic protein (BMP)-4 and BMP-7 suppress
granulosa cell apoptosis via different pathways: BMP-4 via
PI3K/PDK-1/Akt and BMP-7 via PI3K/PDK-1/PKC. Biochem Biophys Res
Commun. 417:869–873. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wang K, Liu D, Zhu TJ, Tang ZG and Dai HY:
BMP9 inhibit the proliferation, invasion and migration of
MDA-MB-231 breast cancer cells through binding ALK2 receptor to
activate BMPs/SMAD cell signaling pathway. Genomics and Applied
Biology. 35:1569–1576. 2016.
|
|
20
|
Bolat Kucukzeybek B, Vedat Bayoglu I,
Kucukzeybek Y, Alacacioglu A, Yigit S, Akder Sari A, Akyol M and
Oktay Tarhan M: The prognostic significance of cyclin D1 expression
in patients with triple-negative breast cancer. J BUON. 22:947–952.
2017.PubMed/NCBI
|
|
21
|
Khan S, Brougham CL, Ryan J, Sahrudin A,
O'Neill G, Wall D, Curran C, Newell J, Kerin MJ and Dwyer RM:
JmiR-379 regulates cyclin B1 expression and is decreased in breast
cancer. PLoS One. 8:e687532013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Guo X, Connick MC, Vanderhoof J, Ishak MA
and Hartley RS: MicroRNA-16 modulates HuR regulation of Cyclin E1
in breast cancer cells. Int J Mol Sci. 16:7112–7132. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang J, Li M, Chen D, Nie J, Xi Y, Yang X,
Chen Y and Yang Z: Expression of C-myc and β-catenin and their
correlation in triple negative breast cancer. Minerva Med.
108:513–517. 2017.PubMed/NCBI
|
|
24
|
Padala C, Tupurani MA, Puranam K, Gantala
S, Shyamala N, Kondapalli MS, Gundapaneni KK, Mudigonda S, Galimudi
RK, Kupsal K, et al: Synergistic effect of collagenase-1 (MMP1),
stromelysin-1 (MMP3) and gelatinase-B (MMP9) gene polymorphisms in
breast cancer. PLoS One. 12:e01844482017. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Li B, Yang Y, Jiang S, Ni B, Chen K and
Jiang L: Adenovirus-mediated overexpression of BMP-9 inhibits human
osteosarcoma cell growth and migration through downregulation of
the PI3K/AKT pathway. Int J Oncol. 41:1809–1819. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pal I and Mandal M: PI3K and Akt as
molecular targets for cancer therapy: Current clinical outcomes.
Acta Pharmacol Sin. 33:1441–1458. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang Z and Guo J: Mechanical induction of
BMP-7 in osteocyte blocks glucocorticoid-induced apoptosis through
PI3K/AKT/GSK3β pathway. Cell Biochem Biophys. 67:567–574. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng Y, Wang X, Wang H, Yan W, Zhang Q
and Chang X: Bone morphogenetic protein 2 inhibits hepatocellular
carcinoma growth and migration through downregulation of the
PI3K/AKT pathway. Tumour Biol. 35:5189–5198. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pancholi S, Lykkesfeldt A, Johnston SRD,
Dowsett M and Martin LA: The interaction of the ER with ERBB2 and
PI3K results in elevated levels of AKT and p90RSK in
tamoxifen-resistant MCF-7 cells. Breast Cancer Res. 7 Suppl
2:P2.082005. View
Article : Google Scholar :
|
|
30
|
Lin M, Bi H, Yan Y, Huang W, Zhang G,
Zhang G, Tang S, Liu Y, Zhang L, Ma J, et al: Parthenolide
suppresses non-small cell lung cancer GLC-82 cells growth via
B-Raf/MAPK/Erk pathway. Oncotarget. 8:23436–23447. 2017.PubMed/NCBI
|
|
31
|
Duan L, Ye L, Wu R, Wang H, Li X, Li H,
Yuan S, Zha H, Sun H, Zhang Y, et al: Inactivation of the
phosphatidylinositol 3-kinase/Akt pathway is involved in
BMP9-mediated tumor-suppressive effects in gastric cancer cells. J
Cell Biochem. 116:1080–1089. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ye L, Kynaston H and Jiang WG: Bone
morphogenetic protein-9 induces apoptosis in prostate cancer cells,
the role of prostate apoptosis response-4. Mol Cancer Res.
6:1594–1606. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dai HY, Xia WY, Zhu TJ, Tang ZG and Wang
K: BMP9 inhibits the proliferation of human lung adenocarcinoma
A549 cells through BMPs/SMAD signaling pathway. TUMOR. 35:997–1005.
2015.
|
|
34
|
Liu P, Man Y, Wang Y and Bao Y: Mechanism
of BMP9 promotes growth of osteosarcoma mediated by the Notch
signaling pathway. Oncol Lett. 11:1367–1370. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Muñoz-Félix JM, Cuesta C, Perretta-Tejedor
N, Subileau M, López-Hernández FJ, López-Novoa JM and
Martínez-Salgado C: Identification of bone morphogenetic protein 9
(BMP9) as a novel profibrotic factor in vitro. Cell Signal.
28:1252–1261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Yuan SX, Wang DX, Wu QX, Ren CM, Li Y,
Chen QZ, Zeng YH, Shao Y, Yang JQ, Bai Y, et al: BMP9/p38 MAPK is
essential for the antiproliferative effect of resveratrol on human
colon cancer. Oncol Rep. 35:939–947. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Herrera B, van Dinther M, TenDijke P and
Inman GJ: Autocrine bone morphogenetic protein-9 signals through
activin receptor-like kinase-2/Smad1/Smad4 to promote ovarian
cancer cell proliferation. Cancer Res. 69:9254–9262. 2009.
View Article : Google Scholar : PubMed/NCBI
|
